Literature DB >> 26709561

Workers' Compensation, Return to Work, and Lumbar Fusion for Spondylolisthesis.

Joshua T Anderson, Arnold R Haas, Rick Percy, Stephen T Woods, Uri M Ahn, Nicholas U Ahn.   

Abstract

Lumbar fusion for spondylolisthesis is associated with consistent outcomes in the general population. However, workers' compensation is a risk factor for worse outcomes. Few studies have evaluated prognostic factors within this clinically distinct population. The goal of this study was to identify prognostic factors for return to work among patients with workers' compensation claims after fusion for spondylolisthesis. The authors used International Classification of Diseases, Ninth Revision, and Current Procedural Terminology codes to identify 686 subjects from the Ohio Bureau of Workers' Compensation who underwent fusion for spondylolisthesis from 1993 to 2013. Positive return to work status was recorded in patients who returned to work within 2 years of fusion and remained working for longer than 6 months. The criteria for return to work were met by 29.9% (n=205) of subjects. The authors used multivariate logistic regression analysis to identify prognostic factors for return to work. Negative preoperative prognostic factors for postoperative return to work included: out of work for longer than 1 year before fusion (P<.001; odds ratio [OR], 0.16); depression (P=.007; OR<0.01); long-term opioid analgesic use (P=.006; OR, 0.41); lumbar stenosis (P=.043; OR, 0.55); and legal representation (P=.042; OR, 0.63). Return to work rates associated with these factors were 9.7%, 0.0%, 10.0%, 29.2%, and 25.0%, respectively. If these subjects were excluded, the return to work rate increased to 60.4%. The 70.1% (n=481) of subjects who did not return to work had markedly worse outcomes, shown by higher medical costs, chronic opioid dependence, and higher rates of failed back syndrome, total disability, and additional surgery. Psychiatric comorbidity increased after fusion but was much higher in those who did not return to work. Future studies are needed to identify how to better facilitate return to work among similar patients with workers' compensation claims. Copyright 2016, SLACK Incorporated.

Entities:  

Mesh:

Year:  2015        PMID: 26709561     DOI: 10.3928/01477447-20151218-01

Source DB:  PubMed          Journal:  Orthopedics        ISSN: 0147-7447            Impact factor:   1.390


  5 in total

1.  Impact of Body Mass Index on Postsurgical Outcomes for Workers' Compensation Patients Undergoing Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Authors:  Madhav R Patel; Kevin C Jacob; Frank A Chavez; Justin T DesLaurier; Hanna Pawlowski; Michael C Prabhu; Nisheka N Vanjani; Kern Singh
Journal:  Int J Spine Surg       Date:  2022-06-20

2.  Influence of psychosocial distress in the results of elective lumbar spine surgery.

Authors:  Vivian Amaral; Luis Marchi; Heber Martim; Rodrigo Amaral; Joes Nogueira-Neto; Ellen Pierro; Leonardo Oliveira; Etevaldo Coutinho; Fernando Marcelino; Nicholai Faulhaber; Rubens Jensen; Luiz Pimenta
Journal:  J Spine Surg       Date:  2017-09

3.  Prevalence and Risk Factors Associated With Long-term Opioid Use After Injury Among Previously Opioid-Free Workers.

Authors:  Zoe Durand; Sarah Nechuta; Shanthi Krishnaswami; Eric L Hurwitz; Melissa McPheeters
Journal:  JAMA Netw Open       Date:  2019-07-03

Review 4.  Does Workers' Compensation Status Affect Outcomes after Lumbar Spine Surgery? A Systematic Review and Meta-Analysis.

Authors:  Fabrizio Russo; Sergio De Salvatore; Luca Ambrosio; Gianluca Vadalà; Luca Fontana; Rocco Papalia; Jorma Rantanen; Sergio Iavicoli; Vincenzo Denaro
Journal:  Int J Environ Res Public Health       Date:  2021-06-07       Impact factor: 3.390

5.  Expectations of Lumbar Surgery Outcomes among Opioid Users Compared with Non-Users.

Authors:  Marie-Jacqueline Reisener; Alexander P Hughes; Paul Schadler; Alexa Forman; Oliver C Sax; Jennifer Shue; Frank P Cammisa; Andrew A Sama; Federico P Girardi; Carol A Mancuso
Journal:  Asian Spine J       Date:  2020-08-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.